CAMRF Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of 33.97% compared to Camurus AB's net margin of -65.15%. Camurus AB's return on equity of 21.63% beat BioArctic AB's return on equity of 59.48%.

Camurus AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Camurus AB has higher upside potential than BioArctic AB, analysts believe Camurus AB is more attractive than BioArctic AB.

Camurus AB has a beta of 0.933, which suggesting that the stock is 6.658% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Camurus AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Camurus AB pays -- of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend.

Camurus AB quarterly revenues are $59.6M, which are larger than BioArctic AB quarterly revenues of $14M. Camurus AB's net income of $20.2M is higher than BioArctic AB's net income of -$9.1M. Notably, Camurus AB's price-to-earnings ratio is 49.63x while BioArctic AB's PE ratio is 30.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Camurus AB is 16.54x versus 15.61x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of 33.97% compared to Camurus AB's net margin of -481.29%. Camurus AB's return on equity of 21.63% beat Hansa Biopharma AB's return on equity of --.

Camurus AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Camurus AB has higher upside potential than Hansa Biopharma AB, analysts believe Camurus AB is more attractive than Hansa Biopharma AB.

Camurus AB has a beta of 0.933, which suggesting that the stock is 6.658% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.764%.

Camurus AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Camurus AB pays -- of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend.

Camurus AB quarterly revenues are $59.6M, which are larger than Hansa Biopharma AB quarterly revenues of $3.2M. Camurus AB's net income of $20.2M is higher than Hansa Biopharma AB's net income of -$15.6M. Notably, Camurus AB's price-to-earnings ratio is 49.63x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Camurus AB is 16.54x versus 12.08x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Vivesto AB has a net margin of 33.97% compared to Camurus AB's net margin of --. Camurus AB's return on equity of 21.63% beat Vivesto AB's return on equity of -23.44%.

Camurus AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Vivesto AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Camurus AB has higher upside potential than Vivesto AB, analysts believe Camurus AB is more attractive than Vivesto AB.

Camurus AB has a beta of 0.933, which suggesting that the stock is 6.658% less volatile than S&P 500. In comparison Vivesto AB has a beta of 32.470, suggesting its more volatile than the S&P 500 by 3147.007%.

Camurus AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vivesto AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Camurus AB pays -- of its earnings as a dividend. Vivesto AB pays out -- of its earnings as a dividend.

Camurus AB quarterly revenues are $59.6M, which are larger than Vivesto AB quarterly revenues of --. Camurus AB's net income of $20.2M is higher than Vivesto AB's net income of -$755.6K. Notably, Camurus AB's price-to-earnings ratio is 49.63x while Vivesto AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Camurus AB is 16.54x versus -- for Vivesto AB. Usually stocks with elevated PS ratios are considered overvalued.

Orexo AB has a net margin of 33.97% compared to Camurus AB's net margin of -33.67%. Camurus AB's return on equity of 21.63% beat Orexo AB's return on equity of -134.37%.

Camurus AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Camurus AB has higher upside potential than Orexo AB, analysts believe Camurus AB is more attractive than Orexo AB.

Camurus AB has a beta of 0.933, which suggesting that the stock is 6.658% less volatile than S&P 500. In comparison Orexo AB has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.934%.

Camurus AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Camurus AB pays -- of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend.

Camurus AB quarterly revenues are $59.6M, which are larger than Orexo AB quarterly revenues of $12.2M. Camurus AB's net income of $20.2M is higher than Orexo AB's net income of -$4.1M. Notably, Camurus AB's price-to-earnings ratio is 49.63x while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Camurus AB is 16.54x versus 1.31x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.